Veradermics MANE
NYSE MANE
$148.63 +4.88 (+3.39%)
At close: Nov 10, 2026 · 4:00 PM EST

Veradermics (MANE) Accumulated Expenses (2024 - 2026)

Updated

Veradermics' Accumulated Expenses was $5.4 million in Q2 2026, down 3.8% from the prior quarter.

Analysis

Veradermics (MANE) Accumulated Expenses (2024 - 2026) Analysis & Trends

At the end of FY2025, Accumulated Expenses at Veradermics came in at $6.98 million, up 182.6% from FY2024.

  • In earlier years, Accumulated Expenses was $2.47 million in FY2024.
  • The Q2 2026 figure marks the lowest quarterly Accumulated Expenses since Q4 2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Veradermics 822.06 Mn -1.33 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 8.16 Mn
Jun 30, 2026 5.40 Mn
Mar 31, 2026 5.61 Mn
Dec 31, 2025 6.98 Mn
Dec 31, 2024 2.47 Mn
API Access

Veradermics Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=MANE&period=max&api_key=YOUR_API_KEY